Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

DTIL – Precision BioSciences, Inc.

Precision BioSciences, Inc.
DTIL
$4.27
Name : Precision BioSciences, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $47,321,112.00
EPSttm : -2.87
finviz dynamic chart for DTIL
Precision BioSciences, Inc.
$4.27
0.75%
$0.0323

Float Short %

6.73

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

-0.03

EPS Last/This Y

-9.79

EPS This/Next Y

1.2

Price

4.32

Target Price

30.5

Analyst Recom

1

Performance Q

-5.29

Relative Volume

1.38

Beta

1.44

Ticker: DTIL




19 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-06-02DTIL5.04N/AN/A0
2025-06-03DTIL5.1N/AN/A0
2025-06-04DTIL5.15N/AN/A0
2025-06-05DTIL5.19N/AN/A0
2025-06-06DTIL5.27N/AN/A0
2025-06-09DTIL5.31N/AN/A0
2025-06-10DTIL5.24N/AN/A0
2025-06-11DTIL5.07N/AN/A0
2025-06-12DTIL5.01N/AN/A0
2025-06-13DTIL4.9N/AN/A0
2025-06-16DTIL5.13N/AN/A0
2025-06-17DTIL4.9N/AN/A0
2025-06-18DTIL4.7N/AN/A0
2025-06-20DTIL4.76N/AN/A0
2025-06-23DTIL4.55N/AN/A0
2025-06-24DTIL4.6N/AN/A0
2025-06-25DTIL4.22N/AN/A0
2025-06-26DTIL4.15N/AN/A0
2025-06-27DTIL4.29N/AN/A0
DateSymbolLastP/C OIP/C VolTotal OI
19 items Current Page1 of 1




19 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-06-02DTIL5.03-147.2- -8.74
2025-06-03DTIL5.15-147.2- -8.74
2025-06-04DTIL5.16-147.2- -8.74
2025-06-05DTIL5.13-147.2- -8.74
2025-06-06DTIL5.39-147.2- -8.74
2025-06-09DTIL5.30-147.2- -8.74
2025-06-10DTIL5.29-147.2- -8.74
2025-06-11DTIL5.15-147.2- -8.74
2025-06-12DTIL5.03-147.2- -8.74
2025-06-13DTIL4.90-147.2- -8.74
2025-06-16DTIL5.12-147.2- -8.74
2025-06-17DTIL4.90-147.2- -8.74
2025-06-18DTIL4.70-147.2- -8.74
2025-06-20DTIL4.79-147.2- -8.74
2025-06-23DTIL4.61-147.2- -8.74
2025-06-24DTIL4.59-147.2- -8.74
2025-06-25DTIL4.22-147.2- -8.74
2025-06-26DTIL4.16-147.2- -8.74
2025-06-27DTIL4.32-147.2- -8.74
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
19 items Current Page1 of 1




18 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-06-02DTIL-1.1611.6721.76
2025-06-03DTIL-1.1611.6721.76
2025-06-04DTIL-1.1611.6721.76
2025-06-05DTIL-1.1611.6721.76
2025-06-06DTIL-1.1611.6721.76
2025-06-09DTIL-1.1612.4221.76
2025-06-10DTIL-1.1612.4221.76
2025-06-11DTIL-1.1612.4219.23
2025-06-12DTIL-1.1612.4219.23
2025-06-13DTIL-1.1612.4219.23
2025-06-16DTIL-1.1612.4219.23
2025-06-18DTIL-1.1612.4219.23
2025-06-20DTIL-1.1612.4219.23
2025-06-23DTIL-1.1612.4219.23
2025-06-24DTIL-1.1612.4219.23
2025-06-25DTIL-1.1612.4219.23
2025-06-26DTIL-1.1612.426.73
2025-06-27DTIL-0.9312.426.73
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
18 items Current Page1 of 1

Last Quarter Act. EPS

-2.21

Avg. EPS Est. Current Quarter

-2.21

Avg. EPS Est. Next Quarter

-2.24

Insider Transactions

-0.93

Institutional Transactions

12.42

Beta

1.44

Average Sales Estimate Current Quarter

6

Average Sales Estimate Next Quarter

5

Fair Value

Quality Score

28

Growth Score

40

Sentiment Score

18

Actual DrawDown %

99.1

Max Drawdown 5-Year %

-99.2

Target Price

30.5

P/E

Forward P/E

PEG

P/S

0.93

P/B

0.92

P/Free Cash Flow

EPS

-2.01

Average EPS Est. Cur. Y​

-8.74

EPS Next Y. (Est.)

-7.55

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-42.99

Relative Volume

1.38

Return on Equity vs Sector %

-68.5

Return on Equity vs Industry %

-50.6

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Precision BioSciences, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 107
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits, as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; and PBGENE-3243 for the treatment of m.3243 associated mitochondrial myopathy. In addition, the company develops PBGENE-NVS (insertion) for sickle cell and beta thalassemia diseases; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LIVER (insertion), a liver directed target; PBGENE-CNS (excision), a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. It has collaboration agreements with Novartis Pharma AG to discover and develop in vivo gene editing products; TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; and iECURE, Inc. to develop ARCUS-based gene-insertion therapies. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
stock quote shares DTIL – Precision BioSciences, Inc. Stock Price stock today
news today DTIL – Precision BioSciences, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch DTIL – Precision BioSciences, Inc. yahoo finance google finance
stock history DTIL – Precision BioSciences, Inc. invest stock market
stock prices DTIL premarket after hours
ticker DTIL fair value insiders trading